Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

7
Axovant Sciences Failed To Mention Critical Information

2018-07-15 seekingalpha - 2
On July 10th 2018 Axovant Sciences (AXON) announced a partnership with Benitec Biopharma (BNTC) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological disorders.
BLT OXB BNTC BNIKF OXBDF AXON BNTCW

19
3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

2018-07-12 zacks - 4
Innovation holds the key in the pharma/biotech sector and most companies have been diverting their resources to develop gene therapy candidates in their goal of finding a cure for difficult and incurable diseases. In the first half of 2018, most pharma/biotech bigwigs and also a number of smaller companies scurried for a lucrative catch in the space either through licensing deals or acquisitions.
BOLD VYGR BLT SLDB ADI NVS BNTC BNIKF PFE ONCE AXON BNTCW

5
Has Benitec Biopharma Sold The Jewel In The Crown?

2018-07-11 seekingalpha
Provides Benitec and its major shareholder, Nant, with opportunity to set new corporate direction if it desires to do so.
BLT BNTC BNIKF AXON BNTCW

11
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

2018-07-11 zacks - 1
Positive data released by bigwig Biogen, Inc. (BIIB - Free Report) from a mid-stage study for the treatment of Alzheimer’s disease created a stir in the biotech sector last week. Among other news, Celgene Corporation (CELG - Free Report) reported positive data on a key pipeline candidate from a late-stage study while Axovant (AXON - Free Report) gained on yet another licensing deal.
XLRN CELGZ BIIB IDRAW BLT IDRA CELG BNTC BNIKF BCRX AXON BNTCW

7
Axovant, Benitec Gain on Licensing Deal for Gene Therapy

2018-07-10 zacks
Shares of Axovant Sciences (AXON - Free Report) gained after it announced a licensing agreement with Benitec Biopharma .
UNP BLT SLDB OXB BNTC BNIKF OXBDF AXON BNTCW

5
Axovant Wins With Key Licensing Agreement

2018-07-09 247wallst
Axovant Sciences Ltd. (NASDAQ: AXON) shares saw a handy gain on Monday after the company announced that it has licensed exclusive global rights to an investigational silence-and-replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD).
BLT BNTC BNIKF AXON BNTCW

5
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

2018-07-09 genengnews
Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured), and five additional Benitec gene therapy candidates for neurological disorders to to Axovant Sciences. [NIH]
BLT OXB BNTC BNIKF OXBDF ONCE BNTCW AXON

1
Axovant Significantly Expands Pipeline with Licensing Deal with Benitec BioPharma

2018-07-09 biospace
Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec BioPharma.
BLT BNTC BNIKF BNTCW

6
Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

2018-07-09 globenewswire - 1
BASEL, Switzerland, July 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and has also entered into a research collaboration for the development of five additional gene therapy products in neurological disorders.
BLT BNTC BNIKF AXON BNTCW

0
Benitec Biopharma Ltd. (BNTC) CEO Greg West on Q3 2018 Results - Earnings Call Transcript

2018-06-01 seekingalpha
Thank you for standing by and welcome to the Benitec Biopharma Quarterly Corporate Update Conference Call.
BLT BNTC BNIKF BNTCW

0
Benitec Biopharma Limited (BNIKF) CEO Greg West on Q3 2018 Results - Earnings Call Transcript

2018-06-01 seekingalpha
Thank you for standing by, and welcome to the Benitec Biopharma Quarterly Corporate Update Conference Call.
BLT BNIKF BNTC BNTCW

105
BNTC / Benitec Biopharma Ltd - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-09 fintel.io
Benitec Biopharma Ltd (NASDAQ:BNTC) has 6 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 63,952 shares. Largest shareholders include Morgan Stanley, Susquehanna International Group, Llp, Renaissance Technologies LLC, UBS Group AG, Atlantic Trust Group, LLC, and Bank Of America Corp /de/.
BAC CARA BNIKF BAC BLT UBS BNTC MS ULSGF BNTCW

179
RNAi For Hepatitis B - A False Hope For A Cure?

2018-04-06 seekingalpha - 1
RNAi is a revolutionary and powerful biotech modality that is being utilized for Chronic Hepatitis B.
GILD ARWR SRPT BNIKF DRNA ARCT BIIB BLT JNJ ABUS IONS BNTC ALNY BNTCW

Related Articles

REPH: Recro Pharma Analysis and Research Report

20h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

21h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...